Skill Indicators Sample Clauses

Skill Indicators. An employee is required to demonstrate some of the following in the performance of his or her work:
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • an ability to organise, practise and complete nursing functions in stable situations with limited direct supervision; • observation and assessment skills to recognise and report deviations from stable conditions; • flexibility in the capacity to undertake work across the broad range of nursing activity and/or competency in a specialised area of practice; and/or • communication and interpersonal skills to assist in meeting psycho-social needs of individuals/groups.
Sample 1Sample 2See All (7)
Skill Indicators. The employee has limited or no practical experience of current situations; and • The employee exercises limited discretionary judgment, not yet developed by practical experience.
Sample 1Sample 2Sample 3See All (4)
Skill Indicators. The employee has limited or no practical experience of current situations; and • The employee exercises limited discretionary judgment, not yet developed by practical experience. Enrolled Nurse—pay point 2 Pay Point 2 refers to the pay point to which an Enrolled Nurse has progressed or has been appointed.
Sample 1Sample 2Sample 3
Skill Indicators.  The employee has limited or no practical experience of current situations; and  The employee exercises limited discretionary judgment, not yet developed by practical experience. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE – PAY POINT 2
Sample 1
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • a developing ability to recognise changes required in nursing activity and in consultation with the RN, implement and record such changes, as necessary; • an ability to relate theoretical concepts to practice; and/or • requiring assistance in complex situations and in determining priorities. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE PAY POINT 3
Sample 1
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • an ability to organise, practise and complete nursing functions in stable situations with limited direct supervision; • observation and assessment skills to recognise and report deviations from stable conditions; • flexibility in the capacity to undertake work across the broad range of nursing activity and/or competency in a specialised area of practice; and/or • communication and interpersonal skills to assist in meeting psycho-social needs of individuals/groups. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE – PAY POINT 4
Sample 1
AutoNDA by SimpleDocs

Related to Skill Indicators

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: n/a meanç ‘not-appIicabIe’, that there iç no defined Performance Standard for the indicator for the applicable year. tbd means a Target, and a Performance Standard, if applicable, will be determined during the applicable year. INDICATOR CATEGORY INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator 2019/20 PERFORMANCE TARGET STANDARD Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 c1 Total Margin (P) 0 cO Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from LHIN Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a SCHEDULE D — PERFORMANCE 2/3 INDICATOR CATEGORY Quality and Resident Safety Indicators INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator Percentage of Residents Who Fell in the Last 30 days (M) 2019/20 PERFORMANCE TARGET STANDARD n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a SCHEDULE D — PERFORMANCE 2.0 LHIN-Specific Performance Obligations 3/3

  • Performance indicators and targets The purpose of the innovation performance indicators and targets is to assist the University and the Commonwealth in monitoring the University's progress against the Commonwealth's objectives and the University's strategies for innovation. The University will report principal performance information and aim to meet the innovation performance indicators and targets set out in the following tables.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Indicators Debt to Asset Ratio (10%) •Cash Flow (10%) •Total Margin (25%) Risk Assessment Results

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Geographical Indications 1. Each Party shall recognise that geographical indications may be protected through a trade xxxx or sui generis system or other legal means in accordance with its laws and regulations.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • For Product Development Projects and Project Demonstrations  Published documents, including date, title, and periodical name.  Estimated or actual energy and cost savings, and estimated statewide energy savings once market potential has been realized. Identify all assumptions used in the estimates.  Greenhouse gas and criteria emissions reductions.  Other non-energy benefits such as reliability, public safety, lower operational cost, environmental improvement, indoor environmental quality, and societal benefits.  Data on potential job creation, market potential, economic development, and increased state revenue as a result of the project.  A discussion of project product downloads from websites, and publications in technical journals.  A comparison of project expectations and performance. Discuss whether the goals and objectives of the Agreement have been met and what improvements are needed, if any.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.